Stockscreener 앱 받기
29.41
6.40%
1.77
시간 외 거래:
29.75
0.34
+1.16%
전일 마감가:
$27.64
열려 있는:
$27.71
하루 거래량:
594.29K
Relative Volume:
1.18
시가총액:
$1.30B
수익:
-
순이익/손실:
$-166.31M
주가수익비율:
-6.5939
EPS:
-4.4602
순현금흐름:
$-160.59M
1주 성능:
+16.48%
1개월 성능:
+23.05%
6개월 성능:
+42.91%
1년 성능:
+57.86%
1일 변동 폭
$27.71
$29.49
1주일 범위
$25.17
$29.49
52주 변동 폭
$16.10
$29.49
Arrivent Biopharma Inc Stock (AVBP) Company Profile
명칭
Arrivent Biopharma Inc
전화
240-780-6356
주소
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
29.41 | 1.22B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-12 | 재개 | BTIG Research | Buy |
| 2025-12-10 | 개시 | BTIG Research | Buy |
| 2025-11-25 | 개시 | Truist | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-03-20 | 개시 | B. Riley Securities | Buy |
| 2025-03-10 | 개시 | Guggenheim | Buy |
| 2024-07-22 | 개시 | Oppenheimer | Outperform |
| 2024-04-30 | 개시 | H.C. Wainwright | Buy |
| 2024-02-20 | 개시 | Citigroup | Buy |
| 2024-02-20 | 개시 | Goldman | Buy |
| 2024-02-20 | 개시 | Jefferies | Buy |
모두보기
Arrivent Biopharma Inc 주식(AVBP)의 최신 뉴스
Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet - MSN
Are you looking for a top momentum pick? Why ArriVent BioPharma, Inc. (AVBP) is a great choice - MSN
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice - Yahoo Finance
Are medical stocks lagging ArriVent BioPharma, Inc. (AVBP) this year? - MSN
Understanding Momentum Shifts in (AVBP) - Stock Traders Daily
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - Yahoo Finance
Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Surprises Report: How does SAPH compare to its peers2026 Macro Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Arrivent Biopharma stock hits 52-week high at 27.25 USD By Investing.com - Investing.com Australia
Arrivent Biopharma stock hits 52-week high at 27.25 USD - Investing.com
ArriVent BioPharma, Inc. (AVBP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet - Yahoo Finance
Wall Street experts predict that ArriVent BioPharma, Inc. (AVBP) may climb by 72.44%. Check this out before making any investment decisions. - Bitget
ArriVent to present preclinical cancer drug data at AACR 2026 - MSN
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest - Yahoo Finance
AVBP Technical Analysis & Stock Price Forecast - Intellectia AI
Avoiding Lag: Real-Time Signals in (AVBP) Movement - Stock Traders Daily
Clear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
Gains Report: Whats next for ArriVent BioPharma Inc stock2026 Technicals & Weekly Breakout Stock Alerts - baoquankhu1.vn
Aug Highlights: How do insiders feel about ArriVent BioPharma IncAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 8.4%Here's Why - MarketBeat
Aug Mood: Can ArriVent BioPharma Inc maintain sales growth2026 Investor Takeaways & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum Shift - Sahm
RONB Should I Buy - intellectia.ai
BCSM Should I Buy - intellectia.ai
GLND Should I Buy - Intellectia AI
DNMXU Should I Buy - Intellectia AI
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year? - Yahoo Finance
ArriVent BioPharma (NASDAQ:AVBP) Upgraded to Strong-Buy at Truist Financial - MarketBeat
MQY Should I Buy - Intellectia AI
VCX Should I Buy - Intellectia AI
Burkina Faso Integrates National Languages into AI Development Strategy - techafricanews.com
Weekly Investment Analysts’ Ratings Changes for ArriVent BioPharma (AVBP) - Defense World
ArriVent to Present Preclinical Cancer Drug Data at AACR 2026 - mychesco.com
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP) - Seeking Alpha
Discipline and Rules-Based Execution in AVBP Response - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $45.00 at B. Riley Financial - MarketBeat
B. Riley Securities Maintains Buy on ArriVent... - Benzinga
Arrivent Biopharma, Aveanna Healthcare Holdings, EQT - TradingView
Weekly Earnings: Is ArriVent BioPharma Inc subject to activist investor interest2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Is ArriVent BioPharma (AVBP) Offering Value After Recent Share Price Pullback? - Sahm
Is ArriVent BioPharma, Inc. (AVBP) stock outpacing its medical peers this year? - MSN
ArriVent BioPharma Unveils Promising Preclinical Data on Firmonertinib and Dual-Target ADC ARR-002 at 2026 AACR Annual Meeting - Minichart
ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Truist Securities Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 - BioSpace
ArriVent Highlights Next-Generation Oncology Data at AACR 2026 - TipRanks
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - The Manila Times
ArriVent to present preclinical data on firmonertinib and dual-target ADC ARR-002 at AACR 2026 - TradingView
Arrivent Biopharma Inc (AVBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):